206 related articles for article (PubMed ID: 37324454)
1. Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma.
Zheng Y; Peng H; Hu X; Ou Y; Wang D; Wang H; Ren S
Front Pharmacol; 2023; 14():1199395. PubMed ID: 37324454
[No Abstract] [Full Text] [Related]
2. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
3. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases.
Szarvas T; Módos O; Niedworok C; Reis H; Szendröi A; Szász MA; Nyirády P
Urol Oncol; 2016 Sep; 34(9):388-98. PubMed ID: 27267737
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
Reis H; van der Vos KE; Niedworok C; Herold T; Módos O; Szendrői A; Hager T; Ingenwerth M; Vis DJ; Behrendt MA; de Jong J; van der Heijden MS; Peyronnet B; Mathieu R; Wiesweg M; Ablat J; Okon K; Tolkach Y; Keresztes D; Nagy N; Bremmer F; Gaisa NT; Chlosta P; Kriegsmann J; Kovalszky I; Timar J; Kristiansen G; Radzun HJ; Knüchel R; Schuler M; Black PC; Rübben H; Hadaschik BA; Schmid KW; van Rhijn BWG; Nyirády P; Szarvas T
Int J Cancer; 2018 Oct; 143(7):1764-1773. PubMed ID: 29672836
[TBL] [Abstract][Full Text] [Related]
5. Immune Microenvironment Characteristics of Urachal Carcinoma and Its Implications for Prognosis and Immunotherapy.
Zhang X; Wang S; Nie RC; Qu C; Chen J; Yang Y; Cai M
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158883
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.
Reis H; Krafft U; Niedworok C; Módos O; Herold T; Behrendt M; Al-Ahmadie H; Hadaschik B; Nyirady P; Szarvas T
Dis Markers; 2018; 2018():7308168. PubMed ID: 29721106
[TBL] [Abstract][Full Text] [Related]
7. Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Varadi M; Nagy N; Reis H; Hadaschik B; Niedworok C; Modos O; Szendroi A; Ablat J; Black PC; Keresztes D; Csizmarik A; Olah C; Gaisa NT; Kiss A; Timar J; Toth E; Csernak E; Gerstner A; Mittal V; Karkampouna S; Kruithof de Julio M; Gyorffy B; Bedics G; Rink M; Fisch M; Nyirady P; Szarvas T
Cancer Med; 2023 Apr; 12(7):9041-9054. PubMed ID: 36670542
[TBL] [Abstract][Full Text] [Related]
8. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy.
Ashley RA; Inman BA; Sebo TJ; Leibovich BC; Blute ML; Kwon ED; Zincke H
Cancer; 2006 Aug; 107(4):712-20. PubMed ID: 16826585
[TBL] [Abstract][Full Text] [Related]
9. Options for diagnosis and treatment of urachal carcinoma.
Zhang J; Wu J
Asia Pac J Clin Oncol; 2013 Jun; 9(2):117-22. PubMed ID: 23046343
[TBL] [Abstract][Full Text] [Related]
10. Value of MRI in evaluating urachal carcinoma: A single center retrospective study.
Das JP; Woo S; Ghafoor S; Andrieu PIC; Ulaner GA; Donahue TF; Goh AC; Vargas HA
Urol Oncol; 2022 Jul; 40(7):345.e9-345.e17. PubMed ID: 35351368
[TBL] [Abstract][Full Text] [Related]
11. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma.
Zaleski MP; Chen H; Roy-Chowdhuri S; Patel KP; Luthra R; Routbort MJ; Kamat AM; Gao J; Siefker-Radtke A; Czerniak B; Guo CC
Am J Clin Pathol; 2022 Aug; 158(2):263-269. PubMed ID: 35467000
[TBL] [Abstract][Full Text] [Related]
12. Preoperative accuracy of diagnostic evaluation of urachal carcinoma.
Ke C; Hu Z; Yang C
Cancer Med; 2023 Apr; 12(8):9106-9115. PubMed ID: 36734315
[TBL] [Abstract][Full Text] [Related]
13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
14. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
[TBL] [Abstract][Full Text] [Related]
15. Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
Riva G; Mian C; Luchini C; Girolami I; Ghimenton C; Cima L; Novelli L; Hanspeter E; Mazzoleni G; Schwienbacher C; Pycha S; D'Elia C; Trenti E; Pycha A; Martignoni G; Hes O; Eccher A; Nesi G; Brunelli M
Virchows Arch; 2019 Jan; 474(1):13-20. PubMed ID: 30302546
[TBL] [Abstract][Full Text] [Related]
16. Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies.
Olah C; Kubik A; Mátrai P; Engh MA; Barna V; Hegyi P; Reis H; Nyirády P; Szarvas T
Urol Oncol; 2024 Jul; 42(7):221.e1-221.e7. PubMed ID: 38627107
[TBL] [Abstract][Full Text] [Related]
17. Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapies.
Benjamin DJ; Kalebasty AR
Rare Tumors; 2023; 15():20363613231189984. PubMed ID: 37465663
[TBL] [Abstract][Full Text] [Related]
18. Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group.
Guerin M; Miran C; Colomba E; Cabart M; Herrmann T; Pericart S; Maillet D; Neuzillet Y; Deleuze A; Coquan E; Laramas M; Thibault C; Abbar B; Mesnard B; Borchiellini D; Dumont C; Boughalem E; Deville JL; Cancel M; Saldana C; Khalil A; Baciarello G; Flechon A; Walz J; Gravis G
Front Oncol; 2023; 13():1110003. PubMed ID: 36741023
[TBL] [Abstract][Full Text] [Related]
19. Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma.
Yang Y; Beeraka NM; Liu J; Zuo X; Wang X; Li T; Fan R
Curr Pharm Des; 2022; 28(41):3404-3412. PubMed ID: 36154597
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others.
Bupathi M; Wu C
J Gastrointest Oncol; 2016 Oct; 7(5):713-720. PubMed ID: 27747085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
